Healthcare / BiotechnologyKOSDAQ
$26800.00
+250.00 (+0.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-9.9B · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$397.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.8%
↓Gross Margin
100.0%
↑Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+101.3%
FCF CAGR
—
FCF margin
-431.9%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.30B · net income $-10.60B · FCF $-9.93B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $2.30B | $2.30B | $2.91B | $1.62B | — | $140.0M |
| Net Income | $-10.60B | $-10.60B | $-9.91B | $-16.78B | $-8.67B | — |
| EBITDA | $-9.57B | $-9.57B | $-8.91B | $-15.87B | $-7.89B | — |
| EPS | — | — | -756.00 | -1293.00 | -668.00 | -654.00 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Operating Margin | -448.0% | -448.0% | -337.0% | -1075.8% | — | — |
| Net Margin | -461.2% | -461.2% | -341.2% | -1037.8% | — | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.41 | 0.41 | 1.34 | 0.76 | 0.00 | — |
| Current Ratio | 6.92 | 6.92 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-9.93B | $-9.93B | $-8.28B | $-17.85B | $-6.87B | — |
| Returns | ||||||
| ROE | -42.8% | -42.8% | -131.8% | -126.8% | -29.0% | — |
| Valuation | ||||||
| P/B | 16.08 | 16.08 | — | — | — | — |
| Growth & Yield | ||||||
| Revenue Growth | -20.9% | -20.9% | 79.7% | — | — | — |
| EPS Growth | — | — | 41.5% | -93.6% | -2.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-756.00 → n/d
Residual
-37.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.